Cell Therapy Market Size, Top Share, Global Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Cell Therapy Market Size Analysis

Global Cell Therapy Market Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
U.S.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Allogenic Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. Hematopoietic Stem Cell Therapies
      1. Hematopoietic Stem Cell Therapies By Value
    4. Mesenchymal Stem Cell Therapies
      1. Mesenchymal Stem Cell Therapies By Value
    5. Non-Stem Cell Therapies
      1. Non-Stem Cell Therapies By Value
    6. Keratinocytes & Fibroblast based therapies
      1. Keratinocytes & Fibroblast based therapies By Value
    7. Others
      1. Others By Value
  3. Autologous Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. BM, Blood, & Umbilical Cord-derived Stem Cells
      1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
    4. Adipose Derived Cells
      1. Adipose Derived Cells By Value
    5. Others
      1. Others By Value
  4. Non-Stem Cell Therapies
    1. By Value
    2. T Cell Therapies
      1. T Cell Therapies By Value
    3. CAR T Cell Therapy
      1. CAR T Cell Therapy By Value
    4. T cell Receptor based
      1. T cell Receptor based By Value
    5. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Musculoskeletal Disorders
    1. By Value
  5. Dermatology
    1. By Value
  6. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
U.K.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Allogenic Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. Hematopoietic Stem Cell Therapies
      1. Hematopoietic Stem Cell Therapies By Value
    4. Mesenchymal Stem Cell Therapies
      1. Mesenchymal Stem Cell Therapies By Value
    5. Non-Stem Cell Therapies
      1. Non-Stem Cell Therapies By Value
    6. Keratinocytes & Fibroblast based therapies
      1. Keratinocytes & Fibroblast based therapies By Value
    7. Others
      1. Others By Value
  3. Autologous Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. BM, Blood, & Umbilical Cord-derived Stem Cells
      1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
    4. Adipose Derived Cells
      1. Adipose Derived Cells By Value
    5. Others
      1. Others By Value
  4. Non-Stem Cell Therapies
    1. By Value
    2. T Cell Therapies
      1. T Cell Therapies By Value
    3. CAR T Cell Therapy
      1. CAR T Cell Therapy By Value
    4. T cell Receptor based
      1. T cell Receptor based By Value
    5. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Musculoskeletal Disorders
    1. By Value
  5. Dermatology
    1. By Value
  6. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
China
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Allogenic Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. Hematopoietic Stem Cell Therapies
      1. Hematopoietic Stem Cell Therapies By Value
    4. Mesenchymal Stem Cell Therapies
      1. Mesenchymal Stem Cell Therapies By Value
    5. Non-Stem Cell Therapies
      1. Non-Stem Cell Therapies By Value
    6. Keratinocytes & Fibroblast based therapies
      1. Keratinocytes & Fibroblast based therapies By Value
    7. Others
      1. Others By Value
  3. Autologous Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. BM, Blood, & Umbilical Cord-derived Stem Cells
      1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
    4. Adipose Derived Cells
      1. Adipose Derived Cells By Value
    5. Others
      1. Others By Value
  4. Non-Stem Cell Therapies
    1. By Value
    2. T Cell Therapies
      1. T Cell Therapies By Value
    3. CAR T Cell Therapy
      1. CAR T Cell Therapy By Value
    4. T cell Receptor based
      1. T cell Receptor based By Value
    5. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Musculoskeletal Disorders
    1. By Value
  5. Dermatology
    1. By Value
  6. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
UAE
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Allogenic Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. Hematopoietic Stem Cell Therapies
      1. Hematopoietic Stem Cell Therapies By Value
    4. Mesenchymal Stem Cell Therapies
      1. Mesenchymal Stem Cell Therapies By Value
    5. Non-Stem Cell Therapies
      1. Non-Stem Cell Therapies By Value
    6. Keratinocytes & Fibroblast based therapies
      1. Keratinocytes & Fibroblast based therapies By Value
    7. Others
      1. Others By Value
  3. Autologous Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. BM, Blood, & Umbilical Cord-derived Stem Cells
      1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
    4. Adipose Derived Cells
      1. Adipose Derived Cells By Value
    5. Others
      1. Others By Value
  4. Non-Stem Cell Therapies
    1. By Value
    2. T Cell Therapies
      1. T Cell Therapies By Value
    3. CAR T Cell Therapy
      1. CAR T Cell Therapy By Value
    4. T cell Receptor based
      1. T cell Receptor based By Value
    5. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Musculoskeletal Disorders
    1. By Value
  5. Dermatology
    1. By Value
  6. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
The rest of MEA

LATAM Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. Allogenic Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. Hematopoietic Stem Cell Therapies
    1. Hematopoietic Stem Cell Therapies By Value
  4. Mesenchymal Stem Cell Therapies
    1. Mesenchymal Stem Cell Therapies By Value
  5. Non-Stem Cell Therapies
    1. Non-Stem Cell Therapies By Value
  6. Keratinocytes & Fibroblast based therapies
    1. Keratinocytes & Fibroblast based therapies By Value
  7. Others
    1. Others By Value
3. Autologous Therapies
  1. By Value
  2. Stem Cell Therapies
    1. Stem Cell Therapies By Value
  3. BM, Blood, & Umbilical Cord-derived Stem Cells
    1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
  4. Adipose Derived Cells
    1. Adipose Derived Cells By Value
  5. Others
    1. Others By Value
4. Non-Stem Cell Therapies
  1. By Value
  2. T Cell Therapies
    1. T Cell Therapies By Value
  3. CAR T Cell Therapy
    1. CAR T Cell Therapy By Value
  4. T cell Receptor based
    1. T cell Receptor based By Value
  5. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Musculoskeletal Disorders
  1. By Value
5. Dermatology
  1. By Value
6. Others
  1. By Value
By Manufacturers
1. Introduction
  1. Manufacturers By Value
2. Biopharmaceutical and biotechnology companies
  1. By Value
3. Pharmaceutical companies
  1. By Value
4. CDMOs/CMOs
  1. By Value
5. Others
  1. By Value
Brazil
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. Allogenic Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. Hematopoietic Stem Cell Therapies
      1. Hematopoietic Stem Cell Therapies By Value
    4. Mesenchymal Stem Cell Therapies
      1. Mesenchymal Stem Cell Therapies By Value
    5. Non-Stem Cell Therapies
      1. Non-Stem Cell Therapies By Value
    6. Keratinocytes & Fibroblast based therapies
      1. Keratinocytes & Fibroblast based therapies By Value
    7. Others
      1. Others By Value
  3. Autologous Therapies
    1. By Value
    2. Stem Cell Therapies
      1. Stem Cell Therapies By Value
    3. BM, Blood, & Umbilical Cord-derived Stem Cells
      1. BM, Blood, & Umbilical Cord-derived Stem Cells By Value
    4. Adipose Derived Cells
      1. Adipose Derived Cells By Value
    5. Others
      1. Others By Value
  4. Non-Stem Cell Therapies
    1. By Value
    2. T Cell Therapies
      1. T Cell Therapies By Value
    3. CAR T Cell Therapy
      1. CAR T Cell Therapy By Value
    4. T cell Receptor based
      1. T cell Receptor based By Value
    5. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Musculoskeletal Disorders
    1. By Value
  5. Dermatology
    1. By Value
  6. Others
    1. By Value
3. By Manufacturers
  1. Introduction
    1. Manufacturers By Value
  2. Biopharmaceutical and biotechnology companies
    1. By Value
  3. Pharmaceutical companies
    1. By Value
  4. CDMOs/CMOs
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Cell Therapy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Novartis AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Amgen Inc.
Vericel Corporation
Gilead Sciences, Inc.
Bluebird Bio, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson and its affilates
Celgene Corporation
ImmunoACT
Cellectis
Astellas Pharma Inc.
Atara Biotherapeutics, Inc.
Sana Biotechnology
Bayer AG
F. Hoffmann-La Roche Ltd
ALLOGENE THERAPEUTICS
Intas Pharmaceuticals Ltd.
EUREKA THERAPEUTICS
Novo Nordisk A/S
Kyverna Therapeutics, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment